N6-methyladenosine-related MicroRNAs Risk Model Trumps the Isocitrate Dehydrogenase Mutation Status As a Predictive Biomarker for the Prognosis and Immunotherapy in Lower Grade Gliomas

Overview

Journal Explor Target Antitumor Ther

Specialty Oncology

Date 2022 Oct 13

PMID 36226036

Authors

Feng Yuan

Yingshuai Wang

Xiangming Cai

Chaonan Du

Junhao Zhu

Chao Tang

Jin Yang

Chiyuan Ma

Affiliations

Soon will be listed here.

Abstract

Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to neurosurgeons. The aim of this study was to explore the N6-methyladenosine (mA) modification landscape in the LGGs and to develop an mA-related microRNA (miRNA) risk model to provide new perspectives for the treatment and prognostic assessment of LGGs.

Methods: Messenger RNA (mRNA) and miRNA expression data of LGGs were extracted from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. An mA-related miRNA risk model was constructed via least absolute shrinkage and selection operator (LASSO), univariate, and multivariate Cox regression analysis. Next, Kaplan-Meier analysis, principal-component analysis (PCA), functional enrichment analysis, immune infiltrate analysis, dynamic nomogram, and drug sensitivity prediction were used to evaluate this risk model.

Results: Firstly, six mA-related miRNAs with independent prognostic value were selected based on clinical information and used to construct a risk model. Subsequently, compared with low-risk group, LGGs in the high-risk group had a higher mA writer and reader scores, but a lower eraser score. Moreover, LGGs in the high-risk group had a significantly worse clinical prognosis than those in the low-risk group. Simultaneously, this risk model outperformed other clinicopathological variables in the prognosis prediction of LGGs. Immune infiltrate analysis revealed that the proportion of M2 macrophages, regulatory T (Treg) cells, and the expression levels of exhausted immune response markers were significantly higher in the high-risk group than in the low-risk group. Finally, this study constructed an easy-to-use and free dynamic nomogram to help clinicians use this risk model to aid in diagnosis and prognosis assessment.

Conclusions: This study developed a mA-related risk model and uncovered two different mA modification landscapes in LGGs. Moreover, this risk model may provide guidance and help in clinical prognosis assessment and immunotherapy response prediction for LGGs.

Citing Articles

The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?.

Spallotta F, Illi B Biomedicines. 2024; 12(11).

PMID: 39595195 PMC: 11591585. DOI: 10.3390/biomedicines12112631.

The "Superoncogene" Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme.

Cencioni C, Scagnoli F, Spallotta F, Nasi S, Illi B Int J Mol Sci. 2023; 24(4).

PMID: 36835628 PMC: 9966483. DOI: 10.3390/ijms24044217.

References

Wen P, Packer R . The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 2021; 23(8):1215-1217. PMC: 8328017. DOI: 10.1093/neuonc/noab120. View

Gittleman H, Sloan A, Barnholtz-Sloan J . An independently validated survival nomogram for lower-grade glioma. Neuro Oncol. 2019; 22(5):665-674. PMC: 7229246. DOI: 10.1093/neuonc/noz191. View

van den Bent M . Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010; 120(3):297-304. PMC: 2910894. DOI: 10.1007/s00401-010-0725-7. View

Stahlhut C, Slack F . MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013; 5(12):111. PMC: 3978829. DOI: 10.1186/gm516. View

Tabibkhooei A, Izadpanahi M, Arab A, Zare-Mirzaei A, Minaeian S, Rostami A . Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas. Clin Neurol Neurosurg. 2020; 190:105652. DOI: 10.1016/j.clineuro.2019.105652. View

Li Y, Xu J, Zhang J, Zhang J, Zhang J, Lu X . MicroRNA-346 inhibits the growth of glioma by directly targeting NFIB. Cancer Cell Int. 2019; 19:294. PMC: 6857291. DOI: 10.1186/s12935-019-1017-5. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Edens B, Vissers C, Su J, Arumugam S, Xu Z, Shi H . FMRP Modulates Neural Differentiation through mA-Dependent mRNA Nuclear Export. Cell Rep. 2019; 28(4):845-854.e5. PMC: 6687293. DOI: 10.1016/j.celrep.2019.06.072. View

Ma C, Nguyen H, Luwor R, Stylli S, Gogos A, Paradiso L . A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker. PLoS One. 2018; 13(2):e0189452. PMC: 5812551. DOI: 10.1371/journal.pone.0189452. View

10.

Qu S, Guan J, Liu Y . Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci. 2014; 348(1-2):181-7. DOI: 10.1016/j.jns.2014.11.036. View

11.

Pyman B, Sedghi A, Azizi S, Tyryshkin K, Renwick N, Mousavi P . Exploring microRNA Regulation of Cancer with Context-Aware Deep Cancer Classifier. Pac Symp Biocomput. 2019; 24:160-171. View

12.

Pan T . N6-methyl-adenosine modification in messenger and long non-coding RNA. Trends Biochem Sci. 2013; 38(4):204-9. PMC: 3608796. DOI: 10.1016/j.tibs.2012.12.006. View

13.

Otmani K, Lewalle P . Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications. Front Oncol. 2021; 11:708765. PMC: 8554338. DOI: 10.3389/fonc.2021.708765. View

14.

Santangelo A, Imbruce P, Gardenghi B, Belli L, Agushi R, Tamanini A . A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2017; 136(1):51-62. DOI: 10.1007/s11060-017-2639-x. View

15.

Zhang J, Bai R, Li M, Ye H, Wu C, Wang C . Excessive miR-25-3p maturation via N-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019; 10(1):1858. PMC: 6478927. DOI: 10.1038/s41467-019-09712-x. View

16.

Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M . TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun. 2020; 8(1):201. PMC: 7685625. DOI: 10.1186/s40478-020-01078-2. View

17.

Speirs C, Simpson J, Robinson C, DeWees T, Tran D, Linette G . Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Int J Radiat Oncol Biol Phys. 2015; 91(2):268-76. DOI: 10.1016/j.ijrobp.2014.10.027. View

18.

Kasinski A, Slack F . Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011; 11(12):849-64. PMC: 4314215. DOI: 10.1038/nrc3166. View

19.

Cen B, Lang J, Du Y, Wei J, Xiong Y, Bradley N . Prostaglandin E Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression. Gastroenterology. 2019; 158(4):971-984.e10. PMC: 7062589. DOI: 10.1053/j.gastro.2019.11.013. View

20.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View